Altimmune slumped 13% premarket after pricing a $225 million public offering at a 13.5% discount. The biotech's second offering this year sparked dilution fears. Proceeds will fund the Phase 3 trial of Pemvidutide for MASH liver disease, which is testing multiple doses over 52 weeks.